Labcorp added to its suite of tests designed to detect cancer recurrence much earlier than traditional imaging.
Medical Device Network on MSN
NAMSA acquires Labcorp’s medical device testing assets
The move adds Labcorp’s US biocompatibility, analytical testing, and preclinical research services to Namsa’s operations.
Quest and Labcorp may be archrivals in the diagnostic testing market, but they appear to agree on at least one thing: the ...
BURLINGTON, North Carolina -- LabCorp has received emergency use authorization from the Food and Drug Administration for its Pixel at home coronavirus test kit. The COVID-19 At Home Test Kit allows ...
NAMSA, a global leader in medical device testing, clinical research, and regulatory consulting, is pleased to announce it has ...
BURLINGTON, N.C.--(BUSINESS WIRE)--Nearly 10 million people in the United States have a history of systemic or anaphylactic reaction to insect stings, with the risk of a severe and potentially ...
BURLINGTON – A new test developed by Labcorp can help people find treatment options for skin cancer. The test, which Labcorp announced in a statement, is available for use in clinical trials and for ...
BURLINGTON, N.C.--(BUSINESS WIRE)--Finding treatment options for skin cancer may become easier with the launch of a new test by Labcorp (NYSE: LH), a leading global life sciences company. The new test ...
Namsa, which is backed by Archimed, has acquired Labcorp’s US-based early development medical testing business. No financial ...
The new test measures the risk of preeclampsia with up to 90% sensitivity and 90% specificity, according to Labcorp. Photo by Adobe Stock/HealthDay News Preeclampsia can be a life-threatening ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback